相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。Meta-analysis of tumor- and T cell-intrinsic mechanisms of sensitization to checkpoint inhibition
Kevin Litchfield et al.
CELL (2021)
The Immunoscore: Colon Cancer and Beyond
Helen K. Angell et al.
CLINICAL CANCER RESEARCH (2020)
Pembrolizumab for advanced anal squamous cell carcinoma (ASCC): Results from the multicohort, phase II KEYNOTE-158 study
Aurelien Marabelle et al.
JOURNAL OF CLINICAL ONCOLOGY (2020)
Genomic basis for RNA alterations in cancer
Claudia Calabrese et al.
NATURE (2020)
Pan-cancer analysis of whole genomes
Peter J. Campbell et al.
NATURE (2020)
The evolutionary history of 2,658 cancers
Moritz Gerstung et al.
NATURE (2020)
The repertoire of mutational signatures in human cancer
Ludmil B. Alexandrov et al.
NATURE (2020)
Interplay between whole-genome doubling and the accumulation of deleterious alterations in cancer evolution
Saioa Lopez et al.
NATURE GENETICS (2020)
HLA-corrected tumor mutation burden and homologous recombination de fi ciency for the prediction of response to PD -(L)1 blockade in advanced non -small -cell lung cancer patients
J. H. Shim et al.
ANNALS OF ONCOLOGY (2020)
Unraveling tumor-immune heterogeneity in advanced ovarian cancer uncovers immunogenic effect of chemotherapy
Alejandro Jimenez-Sanchez et al.
NATURE GENETICS (2020)
Measuring Intratumoral Heterogeneity of Immune Repertoires
Diana Vladimirovna Yuzhakova et al.
FRONTIERS IN ONCOLOGY (2020)
Geospatial immune variability illuminates differential evolution of lung adenocarcinoma
Khalid AbdulJabbar et al.
NATURE MEDICINE (2020)
PD-1 Inhibitors: Do they have a Future in the Treatment of Glioblastoma?
Mustafa Khasraw et al.
CLINICAL CANCER RESEARCH (2020)
Spatial heterogeneity of PD-L1 expression and the risk for misclassification of PD-L1 immunohistochemistry in non-small cell lung cancer
Shani Ben Dori et al.
LUNG CANCER (2020)
Cost effectiveness of immune checkpoint inhibitors for treatment of non-small cell lung cancer: A systematic review
Haiying Ding et al.
PLOS ONE (2020)
Prognostic and Predictive Impact of Circulating Tumor DNA in Patients with Advanced Cancers Treated with Immune Checkpoint Blockade
Qu Zhang et al.
CANCER DISCOVERY (2020)
Pembrolizumab Activity in Recurrent High-Grade Gliomas with Partial or Complete Loss of Mismatch Repair Protein Expression: A Monocentric, Observational and Prospective Pilot Study
Giuseppe Lombardi et al.
CANCERS (2020)
Efficacy of Pembrolizumab in Patients With Noncolorectal High Microsatellite Instability/Mismatch Repair-Deficient Cancer: Results From the Phase II KEYNOTE-158 Study
Aurelien Marabelle et al.
JOURNAL OF CLINICAL ONCOLOGY (2020)
TCR repertoire intratumor heterogeneity of CD4+ and CD8+ T cells in centers and margins of localized lung adenocarcinomas
Chaoting Zhang et al.
INTERNATIONAL JOURNAL OF CANCER (2019)
Exome Analysis Reveals Genomic Markers Associated with Better Efficacy of Nivolumab in Lung Cancer Patients
Corentin Richard et al.
CLINICAL CANCER RESEARCH (2019)
Neoantigen-directed immune escape in lung cancer evolution
Rachel Rosenthal et al.
NATURE (2019)
Intratumor heterogeneity of PD-L1 expression in head and neck squamous cell carcinoma
Jacob H. Rasmussen et al.
BRITISH JOURNAL OF CANCER (2019)
Efficacy and Safety of Pembrolizumab in Previously Treated Advanced Cervical Cancer: Results From the Phase II KEYNOTE-158 Study
Hyun Cheol Chung et al.
JOURNAL OF CLINICAL ONCOLOGY (2019)
Adverse effects of immune-checkpoint inhibitors: epidemiology, management and surveillance
Filipe Martins et al.
NATURE REVIEWS CLINICAL ONCOLOGY (2019)
Cancer stemness, intratumoral heterogeneity, and immune response across cancers
Alex Miranda et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2019)
CANCER Genetic diversity of tumors with mismatch repair deficiency influences anti-PD-1 immunotherapy response
Rajarsi Mandal et al.
SCIENCE (2019)
Augmenting Immunotherapy Impact by Lowering Tumor TNF Cytotoxicity Threshold
David W. Vredevoogd et al.
CELL (2019)
Spatial and Temporal Heterogeneity of Panel-Based Tumor Mutational Burden in Pulmonary Adenocarcinoma: Separating Biology From Technical Artifacts
Daniel Kazdal et al.
JOURNAL OF THORACIC ONCOLOGY (2019)
UVB-Induced Tumor Heterogeneity Diminishes Immune Response in Melanoma
Yochai Wolf et al.
CELL (2019)
Progress in cancer survival, mortality, and incidence in seven high-income countries 1995-2014 (ICBP SURVMARK-2): a population-based study
Melina Arnold et al.
LANCET ONCOLOGY (2019)
Liquid versus tissue biopsy for detecting acquired resistance and tumor heterogeneity in gastrointestinal cancers
Aparna R. Parikh et al.
NATURE MEDICINE (2019)
Neoantigen quality, not quantity
Nicholas McGranahan et al.
SCIENCE TRANSLATIONAL MEDICINE (2019)
An updated review of microsatellite instability in the era of next-generation sequencing and precision medicine
Hiroyuki Yamamoto et al.
SEMINARS IN ONCOLOGY (2019)
Adaptive mutability of colorectal cancers in response to targeted therapies
Mariangela Russo et al.
SCIENCE (2019)
An innate-like Vδ1+ γδ T cell compartment in the human breast is associated with remission in triple-negative breast cancer
Yin Wu et al.
SCIENCE TRANSLATIONAL MEDICINE (2019)
The role of PD-L1 expression as a predictive biomarker: an analysis of all US Food and Drug Administration (FDA) approvals of immune checkpoint inhibitors
Andrew A. Davis et al.
JOURNAL FOR IMMUNOTHERAPY OF CANCER (2019)
γδ T cells in cancer: a small population of lymphocytes with big implications
Mathilde Raverdeau et al.
CLINICAL & TRANSLATIONAL IMMUNOLOGY (2019)
Tumor mutational burden (TMB): Assessment of inter- and intra-tumor heterogeneity.
Jeffrey M. Conroy et al.
JOURNAL OF CLINICAL ONCOLOGY (2019)
NKp46-expressing human gut-resident intraepithelial Vδ1T cell subpopulation exhibits high antitumor activity against colorectal cancer
Joanna Mikulak et al.
JCI INSIGHT (2019)
Comprehensive Intrametastatic Immune Quantification and Major Impact of Immunoscore on Survival
Bernhard Mlecnik et al.
JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE (2018)
Comprehensive Intrametastatic Immune Quantification and Major Impact of Immunoscore on Survival
Bernhard Mlecnik et al.
JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE (2018)
Are liquid biopsies a surrogate for tissue EGFR testing?
J. W. Goldman et al.
ANNALS OF ONCOLOGY (2018)
Comprehensive Characterization of Cancer Driver Genes and Mutations
Matthew H. Bailey et al.
CELL (2018)
Human T Cell Development, Localization, and Function throughout Life
Brahma V. Kumar et al.
IMMUNITY (2018)
Chromosomal instability drives metastasis through a cytosolic DNA response
Samuel F. Bakhoum et al.
NATURE (2018)
Immune recognition of somatic mutations leading to complete durable regression in metastatic breast cancer
Nikolaos Zacharakis et al.
NATURE MEDICINE (2018)
Immune Checkpoint Inhibitors to Treat Malignant Lymphomas
Magdalena Witkowska et al.
JOURNAL OF IMMUNOLOGY RESEARCH (2018)
NKG2D: A Master Regulator of Immune Cell Responsiveness
Felix M. Wensveen et al.
FRONTIERS IN IMMUNOLOGY (2018)
Efficacy and Safety of First-line Avelumab Treatment in Patients With Stage IV Metastatic Merkel Cell Carcinoma A Preplanned Interim Analysis of a Clinical Trial
Sandra P. D'Angelo et al.
JAMA ONCOLOGY (2018)
Safety and Efficacy of Pembrolizumab Monotherapy in Patients With Previously Treated Advanced Gastric and Gastroesophageal Junction Cancer Phase 2 Clinical KEYNOTE-059 Trial
Charles S. Fuchs et al.
JAMA ONCOLOGY (2018)
High response rate to PD-1 blockade in desmoplastic melanomas
Zeynep Eroglu et al.
NATURE (2018)
Successful Treatment of HIV-Associated Kaposi Sarcoma with Immune Checkpoint Blockade
Natalie Galanina et al.
CANCER IMMUNOLOGY RESEARCH (2018)
Defining T Cell States Associated with Response to Checkpoint Immunotherapy in Melanoma
Moshe Sade-Feldman et al.
CELL (2018)
Rejection of immunogenic tumor clones is limited by clonal fraction
Ron S. Gejman et al.
ELIFE (2018)
A systematic review of the cost and cost-effectiveness studies of immune checkpoint inhibitors
Vivek Verma et al.
JOURNAL FOR IMMUNOTHERAPY OF CANCER (2018)
CD4+ T cell help in cancer immunology and immunotherapy
Jannie Borst et al.
NATURE REVIEWS IMMUNOLOGY (2018)
Evolution of Neoantigen Landscape during Immune Checkpoint Blockade in Non-Small Cell Lung Cancer
Valsamo Anagnostou et al.
CANCER DISCOVERY (2017)
IFN-γ-related mRNA profile predicts clinical response to PD-1 blockade
Mark Ayers et al.
JOURNAL OF CLINICAL INVESTIGATION (2017)
Insertion-and-deletion-derived tumour-specific neoantigens and the immunogenic phenotype: a pan-cancer analysis
Samra Turajlic et al.
LANCET ONCOLOGY (2017)
Inactivation of DNA repair triggers neoantigen generation and impairs tumour growth
Giovanni Germano et al.
NATURE (2017)
Identification of unique neoantigen qualities in long-term survivors of pancreatic cancer
Vinod P. Balachandran et al.
NATURE (2017)
cGAS surveillance of micronuclei links genome instability to innate immunity
Karen J. Mackenzie et al.
NATURE (2017)
Mitotic progression following DNA damage enables pattern recognition within micronuclei
Shane M. Harding et al.
NATURE (2017)
Phylogenetic ctDNA analysis depicts early-stage lung cancer evolution
Christopher Abbosh et al.
NATURE (2017)
Cytoplasmic chromatin triggers inflammation in senescence and cancer
Zhixun Dou et al.
NATURE (2017)
Is autoimmunity the Achilles' heel of cancer immunotherapy?
Carl H. June et al.
NATURE MEDICINE (2017)
Radiotherapy and immunotherapy: a beneficial liaison?
Ralph R. Weichselbaum et al.
NATURE REVIEWS CLINICAL ONCOLOGY (2017)
Tracking the Evolution of Non-Small-Cell Lung Cancer
M. Jamal-Hanjani et al.
NEW ENGLAND JOURNAL OF MEDICINE (2017)
Pembrolizumab as Second-Line Therapy for Advanced Urothelial Carcinoma
J. Bellmunt et al.
NEW ENGLAND JOURNAL OF MEDICINE (2017)
cGAS is essential for the antitumor effect of immune checkpoint blockade
Hua Wang et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2017)
Mismatch repair deficiency predicts response of solid tumors to PD-1 blockade
Dung T. Le et al.
SCIENCE (2017)
Tumor aneuploidy correlates with markers of immune evasion and with reduced response to immunotherapy
Teresa Davoli et al.
SCIENCE (2017)
Integrated molecular analysis of tumor biopsies on sequential CTLA-4 and PD-1 blockade reveals markers of response and resistance
Whijae Roh et al.
SCIENCE TRANSLATIONAL MEDICINE (2017)
Chromosomal Instability as a Driver of Tumor Heterogeneity and Evolution
Samuel F. Bakhoum et al.
COLD SPRING HARBOR PERSPECTIVES IN MEDICINE (2017)
Chronic NKG2D Engagement In Vivo Differentially Impacts NK Cell Responsiveness by Activating NK Receptors
Christine Koch et al.
FRONTIERS IN IMMUNOLOGY (2017)
Allele-Specific HLA Loss and Immune Escape in Lung Cancer Evolution
Nicholas McGranahan et al.
CELL (2017)
Tumor and Microenvironment Evolution during Immunotherapy with Nivolumab
Nadeem Riaz et al.
CELL (2017)
Distinct Cellular Mechanisms Underlie Anti-CTLA-4 and Anti-PD-1 Checkpoint Blockade
Spencer C. Wei et al.
CELL (2017)
PD-L1 Expression and Intratumoral Heterogeneity Across Breast Cancer Subtypes and Stages An Assessment of 245 Primary and 40 Metastatic Tumors
Erik A. Dill et al.
AMERICAN JOURNAL OF SURGICAL PATHOLOGY (2017)
Clonal Heterogeneity and Tumor Evolution: Past, Present, and the Future
Nicholas McGranahan et al.
CELL (2017)
Comparative study of the PD-L1 status between surgically resected specimens and matched biopsies of NSCLC patients reveal major discordances: a potential issue for anti-PD-L1 therapeutic strategies
M. Ilie et al.
ANNALS OF ONCOLOGY (2016)
Pan-cancer analysis of the extent and consequences of intratumor heterogeneity
Noemi Andor et al.
NATURE MEDICINE (2016)
Loss of IFN-γ Pathway Genes in Tumor Cells as a Mechanism of Resistance to Anti-CTLA-4 Therapy
Jianjun Gao et al.
CELL (2016)
Tumor Interferon Signaling Regulates a Multigenic Resistance Program to Immune Checkpoint Blockade
Joseph L. Benci et al.
CELL (2016)
Ipilimumab and Bevacizumab in Glioblastoma
T. Carter et al.
CLINICAL ONCOLOGY (2016)
Integrative Analyses of Colorectal Cancer Show Immunoscore Is a Stronger Predictor of Patient Survival Than Microsatellite Instability
Bernhard Mlecnik et al.
IMMUNITY (2016)
Association Between Plasma Genotyping and Outcomes of Treatment With Osimertinib (AZD9291) in Advanced Non-Small-Cell Lung Cancer
Geoffrey R. Oxnard et al.
JOURNAL OF CLINICAL ONCOLOGY (2016)
Tumor cells can follow distinct evolutionary paths to become resistant to epidermal growth factor receptor inhibition
Aaron N. Hata et al.
NATURE MEDICINE (2016)
PD-1 Blockade with Pembrolizumab in Advanced Merkel-Cell Carcinoma
Paul T. Nghiem et al.
NEW ENGLAND JOURNAL OF MEDICINE (2016)
Pembrolizumab versus Chemotherapy for PD-L1-Positive Non-Small-Cell Lung Cancer
Martin Reck et al.
NEW ENGLAND JOURNAL OF MEDICINE (2016)
Clonal neoantigens elicit T cell immunoreactivity and sensitivity to immune checkpoint blockade
Nicholas McGranahan et al.
SCIENCE (2016)
Pan-cancer analysis of intratumor heterogeneity as a prognostic determinant of survival
Luc G. T. Morris et al.
ONCOTARGET (2016)
Classification of Advanced Human Cancers Based on Tumor Immunity in the MicroEnvironment (TIME) for Cancer Immunotherapy
Yu Zhang et al.
JAMA ONCOLOGY (2016)
Quantitative Assessment of the Heterogeneity of PD-L1 Expression in Non-Small-Cell Lung Cancer
Joseph McLaughlin et al.
JAMA ONCOLOGY (2016)
Assessment of tumor mutation burden from >60,000 clinical cancer patients using comprehensive genomic profiling.
Garrett Michael Frampton et al.
JOURNAL OF CLINICAL ONCOLOGY (2016)
Classifying Cancers Based on T-cell Infiltration and PD-L1
Michele W. L. Teng et al.
CANCER RESEARCH (2015)
Subclonal Genomic Architectures of Primary and Metastatic Colorectal Cancer Based on Intratumoral Genetic Heterogeneity
Tae-Min Kim et al.
CLINICAL CANCER RESEARCH (2015)
T cells in the control of organ-specific autoimmunity
Jeffrey A. Bluestone et al.
JOURNAL OF CLINICAL INVESTIGATION (2015)
Interferon α/β Enhances the Cytotoxic Response of MEK Inhibition in Melanoma
Oren Litvin et al.
MOLECULAR CELL (2015)
Melanoma-intrinsic β-catenin signalling prevents anti-tumour immunity
Stefani Spranger et al.
NATURE (2015)
The prognostic landscape of genes and infiltrating immune cells across human cancers
Andrew J. Gentles et al.
NATURE MEDICINE (2015)
Subclonal diversification of primary breast cancer revealed by multiregion sequencing
Lucy R. Yates et al.
NATURE MEDICINE (2015)
PD-1 Blockade in Tumors with Mismatch-Repair Deficiency
D. T. Le et al.
NEW ENGLAND JOURNAL OF MEDICINE (2015)
Pembrolizumab for the Treatment of Non-Small-Cell Lung Cancer
Edward B. Garon et al.
NEW ENGLAND JOURNAL OF MEDICINE (2015)
Nivolumab versus Docetaxel in Advanced Squamous-Cell Non-Small-Cell Lung Cancer
Julie Brahmer et al.
NEW ENGLAND JOURNAL OF MEDICINE (2015)
Combined Nivolumab and Ipilimumab or Monotherapy in Untreated Melanoma
J. Larkin et al.
NEW ENGLAND JOURNAL OF MEDICINE (2015)
Genomic correlates of response to CTLA-4 blockade in metastatic melanoma
Eliezer M. Van Allen et al.
SCIENCE (2015)
Mutational landscape determines sensitivity to PD-1 blockade in non-small cell lung cancer
Naiyer A. Rizvi et al.
SCIENCE (2015)
Clonal status of actionable driver events and the timing of mutational processes in cancer evolution
Nicholas McGranahan et al.
SCIENCE TRANSLATIONAL MEDICINE (2015)
Association of Polymerase e-Mutated and Microsatellite-Instable Endometrial Cancers With Neoantigen Load, Number of Tumor-Infiltrating Lymphocytes, and Expression of PD-1 and PD-L1
Brooke E. Howitt et al.
JAMA ONCOLOGY (2015)
Heterogeneity of PIK3CA mutational status at the single cell level in circulating tumor cells from metastatic breast cancer patients
Marta Pestrin et al.
MOLECULAR ONCOLOGY (2015)
PD-L1 expression in melanoma shows marked heterogeneity within and between patients: implications for anti-PD-1/PD-L1 clinical trials
Jason Madore et al.
PIGMENT CELL & MELANOMA RESEARCH (2015)
Type I interferons in anticancer immunity
Laurence Zitvogel et al.
NATURE REVIEWS IMMUNOLOGY (2015)
The Immunological Synapse: A Molecular Machine Controlling T Cell Activation
Arash Grakoui et al.
JOURNAL OF IMMUNOLOGY (2015)
Checkpoint blockade cancer immunotherapy targets tumour-specific mutant antigens
Matthew M. Gubin et al.
NATURE (2014)
Predictive correlates of response to the anti-PD-L1 antibody MPDL3280A in cancer patients
Roy S. Herbst et al.
NATURE (2014)
PD-1 blockade induces responses by inhibiting adaptive immune resistance
Paul C. Tumeh et al.
NATURE (2014)
Genetic Basis for Clinical Response to CTLA-4 Blockade in Melanoma
Alexandra Snyder et al.
NEW ENGLAND JOURNAL OF MEDICINE (2014)
Copy Number Loss of the Interferon Gene Cluster in Melanomas Is Linked to Reduced T Cell Infiltrate and Poor Patient Prognosis
Peter S. Linsley et al.
PLOS ONE (2014)
Mutational Analysis Reveals the Origin and Therapy-Driven Evolution of Recurrent Glioma
Brett E. Johnson et al.
SCIENCE (2014)
Cancer Immunotherapy Based on Mutation-Specific CD4+T Cells in a Patient with Epithelial Cancer
Eric Tran et al.
SCIENCE (2014)
Spatial and temporal diversity in genomic instability processes defines lung cancer evolution
Elza C. de Bruin et al.
SCIENCE (2014)
Evolution and Impact of Subclonal Mutations in Chronic Lymphocytic Leukemia
Dan A. Landau et al.
CELL (2013)
Lessons from the Cancer Genome
Levi A. Garraway et al.
CELL (2013)
The Continuum of Cancer Immunosurveillance: Prognostic, Predictive, and Mechanistic Signatures
Jerome Galon et al.
IMMUNITY (2013)
Promotion and prevention of autoimmune disease by CD8+T cells
David M. Gravano et al.
JOURNAL OF AUTOIMMUNITY (2013)
Ultra-deep T cell receptor sequencing reveals the complexity and intratumour heterogeneity of T cell clones in renal cell carcinomas
Marco Gerlinger et al.
JOURNAL OF PATHOLOGY (2013)
Mutational heterogeneity in cancer and the search for new cancer-associated genes
Michael S. Lawrence et al.
NATURE (2013)
The causes and consequences of genetic heterogeneity in cancer evolution
Rebecca A. Burrell et al.
NATURE (2013)
Signatures of mutational processes in human cancer
Ludmil B. Alexandrov et al.
NATURE (2013)
Digital Genomic Quantification of Tumor-Infiltrating Lymphocytes
Harlan S. Robins et al.
SCIENCE TRANSLATIONAL MEDICINE (2013)
Dissection of T-cell Antigen Specificity in Human Melanoma
Rikke Sick Andersen et al.
CANCER RESEARCH (2012)
The Life History of 21 Breast Cancers
Serena Nik-Zainal et al.
CELL (2012)
Intratumoral Molecular Heterogeneity in a BRAF-Mutant, BRAF Inhibitor-Resistant Melanoma: A Case Illustrating the Challenges for Personalized Medicine
James S. Wilmott et al.
MOLECULAR CANCER THERAPEUTICS (2012)
The molecular evolution of acquired resistance to targeted EGFR blockade in colorectal cancers
Luis A. Diaz et al.
NATURE (2012)
Comprehensive molecular characterization of human colon and rectal cancer
Donna M. Muzny et al.
NATURE (2012)
Expression of tumour-specific antigens underlies cancer immunoediting
Michel DuPage et al.
NATURE (2012)
Immunologic Correlates of the Abscopal Effect in a Patient with Melanoma
Michael A. Postow et al.
NEW ENGLAND JOURNAL OF MEDICINE (2012)
Intratumor Heterogeneity and Branched Evolution Revealed by Multiregion Sequencing
Marco Gerlinger et al.
NEW ENGLAND JOURNAL OF MEDICINE (2012)
Safety, Activity, and Immune Correlates of Anti-PD-1 Antibody in Cancer
Suzanne L. Topalian et al.
NEW ENGLAND JOURNAL OF MEDICINE (2012)
EGFR Mutation Heterogeneity and the Mixed Response to EGFR Tyrosine Kinase Inhibitors of Lung Adenocarcinomas
Zhi-Yong Chen et al.
ONCOLOGIST (2012)
Mechanisms of Acquired Crizotinib Resistance in ALK-Rearranged Lung Cancers
Ryohei Katayama et al.
SCIENCE TRANSLATIONAL MEDICINE (2012)
Paradoxical Relationship between Chromosomal Instability and Survival Outcome in Cancer
Nicolai J. Birkbak et al.
CANCER RESEARCH (2011)
Mechanisms of tolerance
Jeffrey A. Bluestone
IMMUNOLOGICAL REVIEWS (2011)
Improved Survival with Vemurafenib in Melanoma with BRAF V600E Mutation
Paul B. Chapman et al.
NEW ENGLAND JOURNAL OF MEDICINE (2011)
Recombination centres and the orchestration of V(D)J recombination
David G. Schatz et al.
NATURE REVIEWS IMMUNOLOGY (2011)
Preexistence and Clonal Selection of MET Amplification in EGFR Mutant NSCLC
Alexa B. Turke et al.
CANCER CELL (2010)
Natural Killer Cell Education and Tolerance
Mark T. Orr et al.
CELL (2010)
The patterns and dynamics of genomic instability in metastatic pancreatic cancer
Peter J. Campbell et al.
NATURE (2010)
Distant metastasis occurs late during the genetic evolution of pancreatic cancer
Shinichi Yachida et al.
NATURE (2010)
Melanomas acquire resistance toB-RAF(V600E) inhibition by RTK or N-RAS upregulation
Ramin Nazarian et al.
NATURE (2010)
Autoimmunity: increasing suspects in the CD4(+) T cell lineup
Matthew T. Palmer et al.
NATURE IMMUNOLOGY (2010)
Improved Survival with Ipilimumab in Patients with Metastatic Melanoma
F. Stephen Hodi et al.
NEW ENGLAND JOURNAL OF MEDICINE (2010)
Comprehensive assessment of T-cell receptor β-chain diversity in αβ T cells
Harlan S. Robins et al.
BLOOD (2009)
Noninvasive Detection of EGFR T790M in Gefitinib or Erlotinib Resistant Non-Small Cell Lung Cancer
Yanan Kuang et al.
CLINICAL CANCER RESEARCH (2009)
MSH6 Mutations Arise in Glioblastomas during Temozolomide Therapy and Mediate Temozolomide Resistance
Stephen Yip et al.
CLINICAL CANCER RESEARCH (2009)
Merkel cell carcinoma of the skin: pathological and molecular evidence for a causative role of MCV in oncogenesis
Xavier Sastre-Garau et al.
JOURNAL OF PATHOLOGY (2009)
Sustained NKG2D engagement induces cross-tolerance of multiple distinct NK cell activation pathways
Jerome D. Coudert et al.
BLOOD (2008)
Subclonal phylogenetic structures in cancer revealed by ultra-deep sequencing
Peter J. Campbell et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2008)
Genomic Analysis of the Clonal Origins of Relapsed Acute Lymphoblastic Leukemia
Charles G. Mullighan et al.
SCIENCE (2008)
MET amplification leads to gefitinib resistance in lung cancer by activating ERBB3 signaling
Jeffrey A. Engelman et al.
SCIENCE (2007)
Loss of the mismatch repair protein MSH6 in human glioblastomas is associated with tumor progression during temozolomide treatment
Daniel P. Cahill et al.
CLINICAL CANCER RESEARCH (2007)
Relative impact of nucleotide and copy number variation on gene expression phenotypes
Barbara E. Stranger et al.
SCIENCE (2007)
Type, density, and location of immune cells within human colorectal tumors predict clinical outcome
Jerom Galon et al.
SCIENCE (2006)
The DNA damage pathway regulates innate immune system ligands of the NKG2D receptor
S Gasser et al.
NATURE (2005)
T cell receptor binding kinetics required for T cell activation depend on the density of cognate ligand on the antigen-presenting cell
PA González et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2005)
EGFR mutation and resistance of non-small-cell lung cancer to gefitinib
S Kobayashi et al.
NEW ENGLAND JOURNAL OF MEDICINE (2005)
Ionizing radiation inhibition of distant untreated tumors (abscopal effect) is immune mediated
S Demaria et al.
INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS (2004)
EGFR mutations in lung cancer:: Correlation with clinical response to gefitinib therapy
JG Paez et al.
SCIENCE (2004)
Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib
TJ Lynch et al.
NEW ENGLAND JOURNAL OF MEDICINE (2004)
The distinct contributions of murine T cell receptor (TCR)γδ+ and TCRαβ+ T cells to different stages of chemically induced skin cancer
M Girardi et al.
JOURNAL OF EXPERIMENTAL MEDICINE (2003)
Medical progress - Skin cancers after organ transplantation
S Euvrard et al.
NEW ENGLAND JOURNAL OF MEDICINE (2003)
Intratumoral T cells, recurrence, and survival in epithelial ovarian cancer
L Zhang et al.
NEW ENGLAND JOURNAL OF MEDICINE (2003)
Involvement of PD-L1 on tumor cells in the escape from host immune system and tumor immunotherapy by PD-L1 blockade
Y Iwai et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2002)
A critical role for natural killer T cells in immunosurveillance of methylcholanthrene-induced sarcomas
NY Crowe et al.
JOURNAL OF EXPERIMENTAL MEDICINE (2002)
Mutations of the BRAF gene in human cancer
H Davies et al.
NATURE (2002)
Regulation of cutaneous malignancy by γδ T cells
M Girardi et al.
SCIENCE (2001)
IFNγ and lymphocytes prevent primary tumour development and shape tumour immunogenicity
V Shankaran et al.
NATURE (2001)
PD-L2 is a second ligand for PD-I and inhibits T cell activation
Y Latchman et al.
NATURE IMMUNOLOGY (2001)
Efficient cell activation requires an optimal dwell-time of interaction between the TCR and the pMHC complex
AM Kalergis et al.
NATURE IMMUNOLOGY (2001)
分享论文
